 |
 |

Superselective Neck Dissection After ChemoradiationFeasibility Based on Clinical and Pathologic Comparisons
K. Thomas Robbins, MD;
Kerwin Shannon, MD;
Francisco Vieira, MD
Arch Otolaryngol Head Neck Surg. 2007;133(5):486-489.
Objective To determine whether superselective neck dissection (removal of 2 or less contiguous neck levels) is effective salvage surgery for patients with residual single-level adenopathy after concomitant intra-arterial cisplatin and radiotherapy.
Design Analysis of prospectively collected data.
Subjects The study group comprised 177 patients (239 heminecks) with N+ disease.
Interventions Intra-arterial treatment with cisplatin (150 mg/m2) on days 1, 8, 15, and 22 and radiation therapy (2 Gy/d) 5 times per week for 7 weeks. Comparisons were made between neck-level–specific disease at restaging and pathologic disease after neck dissection.
Results Tumor sites included oropharynx (n = 81), hypopharynx (39), larynx (n=27), oral cavity (n = 19), and other (n = 11). Response of nodal disease based on clinical evaluation was as follows: complete response, 89 patients (50%); partial response, 81 patients (46%); progressive disease, 4 patients (2%); and unevaluable, 3 patients (2%). Of the 89 patients whose necks were restaged as a partial response, 73 had clinical evidence of residual adenopathy involving only 1 neck level. Within this subset, 54 patients (57 heminecks) subsequently underwent a salvage neck dissection, for which comparisons were made between the restaging evidence of residual adenopathy and the pathologic findings that were specific for each neck level. Only 2 of the 54 patients had evidence of pathologic disease extending beyond the single neck level: one had disease in a contiguous neck level, and the other had disease in a noncontiguous level. The use of superselective neck dissection with removal of only 2 contiguous neck levels would have encompassed known disease in all but 1 patient.
Conclusion Superselective neck dissection is feasible after this specific chemoradiation protocol has been administered to patients with persistent nodal disease that is confined to 1 level.
Author Affiliations: Division of Otolaryngology–Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield (Dr Robbins); Sydney Head and Neck Cancer Institute, Sydney, Australia (Dr Shannon); and Department of Otolaryngology–Head and Neck Surgery, University of Tennessee, Memphis (Dr Vieira).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Neck Response to Chemoradiotherapy: Complete Radiographic Response Correlates With Pathologic Complete Response in Locoregionally Advanced Head and Neck Cancer
Langerman et al.
Arch Otolaryngol Head Neck Surg 2009;135:1133-1136.
ABSTRACT
| FULL TEXT
PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma
Schoder et al.
JNM 2009;50:74S-88S.
ABSTRACT
| FULL TEXT
|